Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kodiak Sciences Inc (KOD)
NASDAQ:KOD
Holding KOD?
Track your performance easily
KOD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.19 - $7.77
Previous Close$5.9
Volume266.56K
Average Volume (3M)262.15K
Market Cap
$310.48M
Enterprise Value$186.05M
Total Cash (Recent Filing)$197.86M
Total Debt (Recent Filing)$73.44M
Price to Earnings (P/E)―
Beta3.72
Next Earnings
Mar 27, 2025EPS Estimate
-$0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.65
Shares Outstanding52,623,774
10 Day Avg. Volume484,953
30 Day Avg. Volume262,152
Standard Deviation0.33
R-Squared0.13
Alpha0.00216
Financial Highlights & Ratios
Price to Book (P/B)1.65
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.13
Forecast
1Y Price Target
$3.00Price Target Upside-51.53% Downside
Rating ConsensusHold
Number of Analyst Covering4
Kodiak Sciences News
PremiumCompany Announcements
Kodiak Sciences Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe KSI-101 dose-finding Phase 1b APEX trial establishes the foundation for initiating pivotal studies, advancing novel treatments for retinal conditions.
Product DevelopmentKSI-101 as a first-in-class bispecific protein aims to address retinal fluid and inflammation, signaling innovation in the treatment of MESI patients.
Research And DevelopmentKodiak Sciences is actively recruiting for Phase 3 trials in key areas like diabetic retinopathy, showing commitment to advancing treatments for major retinal diseases.
Bears Say
Clinical TrialsInvestors are reminded of the prior late-stage failures for tarcocimab in the Phase 3 GLEAM and GLIMMER trials in DME, unexpected increase in cataract AEs over time for tarcocimab, and the Phase 2b/3 DAZZLE trial failure in wet AMD.
Market CompetitionThe retinal disease landscape continues to evolve with many differentiated approaches creating further headwinds for ABCD conjugate positioning.
Product FormulationThe former tarcocimab formulation had a detrimental gel-like formulation that required extended delivery time and force, with potential lens mechanical insult.
---
Ownership Overview
34.81% Insiders
8.58% Mutual Funds
46.03% Other Institutional Investors
3.50% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KOD FAQ
What was Kodiak Sciences Inc’s price range in the past 12 months?
Kodiak Sciences Inc lowest stock price was $2.19 and its highest was $7.77 in the past 12 months.
What is Kodiak Sciences Inc’s market cap?
Currently, no data Available
When is Kodiak Sciences Inc’s upcoming earnings report date?
Kodiak Sciences Inc’s upcoming earnings report date is Mar 27, 2025 which is in 124 days.
How were Kodiak Sciences Inc’s earnings last quarter?
Kodiak Sciences Inc released its earnings results on Nov 14, 2024. The company reported -$0.84 earnings per share for the quarter, beating the consensus estimate of -$0.905 by $0.065.
Is Kodiak Sciences Inc overvalued?
According to Wall Street analysts Kodiak Sciences Inc’s price is currently Overvalued.
Does Kodiak Sciences Inc pay dividends?
Kodiak Sciences Inc does not currently pay dividends.
What is Kodiak Sciences Inc’s EPS estimate?
Kodiak Sciences Inc’s EPS estimate is -$0.91.
How many shares outstanding does Kodiak Sciences Inc have?
Kodiak Sciences Inc has 52,623,775 shares outstanding.
What happened to Kodiak Sciences Inc’s price movement after its last earnings report?
Kodiak Sciences Inc reported an EPS of -$0.84 in its last earnings report, beating expectations of -$0.905. Following the earnings report the stock price went up 4.34%.
Which hedge fund is a major shareholder of Kodiak Sciences Inc?
Among the largest hedge funds holding Kodiak Sciences Inc’s share is Baker Bros Advisors LP. It holds Kodiak Sciences Inc’s shares valued at 45M.
---
Kodiak Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (-51.53% Downside)
$3.00 (-51.53% Downside)
Blogger Sentiment
Neutral
KOD Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 17.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
162.22%
12-Months-Change
Fundamentals
Return on Equity
-78.57%
Trailing 12-Months
Asset Growth
-31.95%
Trailing 12-Months
Company Description
Kodiak Sciences Inc
Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
---
KOD Company Deck
---
KOD Earnings Call
Q4 2024
0:00 / 0:00
---
KOD Stock 12 Month Forecast
Average Price Target
$3.00
▼(-51.53% Downside)
Technical Analysis
Apellis Pharmaceuticals
―
Atara Biotherapeutics
―
Fate Therapeutics
―
Allogene Therapeutics
―
Best Analysts Covering KOD
1 Year
1 Year Success Rate
9/16 ratings generated profit
1 Year Average Return
+20.42%
reiterated a sell rating 8 days ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +20.42% per trade.
---